MedTrace Logo

TRANSEURO Open Label Transplant Study in Parkinson's Disease

NCT01898390 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-05-25

No results posted yet for this study

Summary

The Transeuro Transplant study is a trial which will involve grafting foetal tissue into the brain of patients with Parkinson's disease, who are already been followed in the observational study. The tissue inserted in the brain is to help replace and rebuild lost dopamine from the brain due to Parkinson's disease.

Update April 2019:

A total of 11 PD patients were grafted in Cambridge, UK and Lund, Sweden. No further surgeries are planned. The final patient will complete the study's clinical endpoint (36 months post-graft) in 2021. We continue to assess these patients bi-annually alongside a control group which did not receive any intervention.

Conditions

Interventions

PROCEDURE

Transplant

Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Cardiff University

    collaborator OTHER

  • Imperial College London

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • Life Science Governance Institute

    collaborator UNKNOWN

  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Life Technologies Ltd, part of Thermo Fisher Scientific

    collaborator UNKNOWN

  • Inomed

    collaborator UNKNOWN

  • Cambridge Cognition Ltd

    collaborator INDUSTRY

  • Skane University Hospital

    collaborator OTHER

  • Imanova Limited

    collaborator UNKNOWN

  • University of Cambridge

    lead OTHER

Principal Investigators

  • Roger Barker, Prof · Department of Clinical Neurosciences, University of Cambridge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2022-12-31
Completion
2022-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01898390 on ClinicalTrials.gov